Cargando…
Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis
Results from the STREAM stage 1 trial showed that a 9-month regimen for patients with rifampicin-resistant tuberculosis was non-inferior to the 20-month regimen recommended by the 2011 WHO treatment guidelines. Similar levels of severe adverse events were reported on both regimens suggesting the nee...
Autores principales: | Goodall, Ruth L., Sanders, Karen, Bronson, Gay, Gurumurthy, Meera, Torrea, Gabriela, Meredith, Sarah, Nunn, Andrew, Rusen, I. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171092/ https://www.ncbi.nlm.nih.gov/pubmed/35672833 http://dx.doi.org/10.1186/s13063-022-06397-4 |
Ejemplares similares
-
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
por: Goodall, Ruth L, et al.
Publicado: (2022) -
Implementation challenges and lessons learned from the STREAM clinical trial—a survey of trial sites
por: Patel, Leena N., et al.
Publicado: (2023) -
Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
por: Phillips, P. P. J., et al.
Publicado: (2020) -
QT prolongation in the STREAM Stage 1 Trial
por: Hughes, G., et al.
Publicado: (2022) -
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial
por: Nunn, Andrew J, et al.
Publicado: (2014)